China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
WALTHAM, Mass., June 07, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos Verdes, California. Tim Pearson, EVP and CFO of TESARO, will present at 10:40 AM PT on June 15 and will participate in meetings with investors.
A live webcast of the presentation will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
